Medtronic (MDT) announced CMS granted a New Technology Add-on Payment (NTAP) for its INFUSE™ Bone Graft for TLIF, effective October 1, 2026
Medtronic (MDT) announced CMS granted a New Technology Add-on Payment (NTAP) for its INFUSE™ Bone Graft for TLIF, effective October 1, 2026. NTAP provides additional reimbursement for hospitals using new technologies, supporting adoption and patient access. INFUSE™ is the first and only growth factor technology approved for spine fusion procedures, receiving FDA approval earlier this year. This milestone highlights Medtronic's commitment to advancing healthcare innovation and expanding access to
How this was made
The 30-second read
Why it matters
The reimbursement add‑on reduces financial risk for hospitals, likely accelerating INFUSE™ sales.
Market read
A new CMS reimbursement pathway could materially improve Medtronic's spine revenue outlook.
What to watch
Potential competition from emerging biologic grafts could limit market share gains.
Background
Medtronic announced the NTAP decision as part of its ongoing effort to expand spine product adoption.
Ticker impact
CMS granted a New Technology Add-on Payment for Medtronic's INFUSE™ Bone Graft for TLIF, improving reimbursement.
potential upside as investors price in higher revenue from spine segment
Reimbursement support removes a key barrier for a high‑margin product in a large market.
Market effects
May encourage other spine device makers to seek NTAP status, influencing the broader medical device sector.
Supports U.S. hospital adoption of advanced spine technologies, modestly boosting U.S. healthcare spending.
Highlights CMS's role in shaping global med‑tech reimbursement trends.
Counterpoint
If CMS later tightens NTAP criteria, the initial boost could be short‑lived.
Key entities
- CompanyMedtronic plc
Global medical technology firm.
- RegulatorCenters for Medicare & Medicaid Services (CMS)
U.S. federal agency overseeing Medicare reimbursement.
